EU Chip Industry Faces Growing Risks From China Export Controls and U.S. Technology Dependence: Report 
DOJ Seeks Dismissal of Fraud Charges Against Gautam Adani in U.S. Court 
ShareChat Eyes 2027 IPO After Reaching Operational Profitability, Report Says 
Kawasaki Heavy Shares Slide on Report of ¥200 Billion Capital Raise Plan 
Apple Expands iPhone Lineup, Boosts Foldable iPhone Production Plans Through 2027 
Anthropic Tightens AI Access Controls After Reports of China-Based Workarounds 
OpenAI Proposes 5% U.S. Government Stake Amid AI Policy Talks 
SK Holdings, KKR Launch $1.3B Renewable Energy Venture in South Korea 
Northern Star Appoints New CEO as Activist Elliott Pushes for Leadership Overhaul 
Apple Eyes Chinese Memory Chips as AI Shortage Pressures iPhone Supply Chain 
Lockheed Martin Emerges as Frontrunner to Acquire Ultra Maritime in $3.5 Billion Defense Deal 
Tesla Q2 Deliveries Lift Chinese Auto Suppliers as EV Demand Improves 
Trump Administration to Launch Voluntary AI Standards for Frontier Models 
BHP Workers Approve New Labour Agreement at WA Iron Ore Operations 
Switch Seeks $2 Billion Funding at Nearly $50 Billion Valuation Ahead of Potential IPO 
Meta Stock Jumps as AI Cloud Expansion Challenges AWS, Microsoft, and Google 
Kioxia Bets on AI Memory Boom With Next-Gen NAND Production in Japan 
The US International Trade Commission (ITC) upheld its preliminary ruling saying that South Korean drugmaker Daewoong Pharmaceutical Co. copied the manufacturing process of a botulinum toxin strain by local rival Medytox Inc. in Medytox Medytox
Consequently, the US trade panel ordered a 21-month ban on imports of Daewoong Pharmaceutical's botulinum products into the US.
ITC's ruling, however, reduces the initial 10-year ban prescribed by the preliminary panel that ruled that Daewoong's misappropriated trade secrets belonging to Medytox.
Medytox Inc. claimed that Daewoong's Jeuveau was developed using a trade secret stolen from it that turns the deadly botulinum toxin into a wrinkle treatment.
Daewoong denied any theft allegations or that any trade secret was involved and argued the US agency is not the proper forum to decide on the dispute.
